Bulk order Acrobiosystems for Chinese

Chinese

A-Z

SARS-CoV-2 | CD24 | CD73 | Trimer | CD19 | PD-1

There is no goods in the shopping cart !

My Cart

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

Home
Product & Service

Products by Category

Recombinant proteins and more
FDA DMF Filed ProteinsHot SARS-CoV-2 Related ProductsHot Immune Checkpoint ProteinsHot Targets of CAR-T Cell TherapyNew Biosimilar Drug TargetsHot Tumor MicroenvironmentHot Anti-idiotypic AntibodyHot Fc Receptor Proteins Llama IgG Fc Fusion ProteinNew Bio-Markers & CD Antigens ActiveMax -Best Cytokines Viral Proteins Enzymes Antibodies All Recombinant Proteins
Services

Innovation Lab ServicesNew SPR /BLI analytical serviceNew

Pre-labeled proteins
Biotinylated protein collectionHot FITC & PE labeled ProteinsNew Fluorescent fusion proteins
Kits
SARS-CoV-2 Related Kit ProductsNew Pre-Coupling Magnetic BeadsNew Universal ELISA KitsNew ELISA Assay Kits for Quantitative Analysis of Therapeutic Antibodies in Serum SamplesNew Inhibitor Screening Kits
Others
HPLC-verified Proteins Integrin - Integrin Proteins BCMA - B-Cell Maturation Antigen TIGIT - TIGIT Signaling Axis CD24 & Siglec-10 proteinsHot

Hot Products

Supports on COVID-19 R&D
Reagents for vaccine developmentNew Reagents for diagnostic developmentNew SARS-CoV-2 related productsNew SARS-CoV-2 related kitsNew SARS-CoV-2 spike mutantsNew
Others
Bispecific antibody targetsHot Targets for ADCsHot IL-2 ReceptorsHot CD19 proteinsHot Anti-FMC63 mAbHot CD3 proteinsHot B7 family proteinsHot TNFSF proteinsHot VEGF proteinsHot CD39/CD73 proteinsNew Siglec-15 proteinsHot CD20 proteinsExclusive PD1 proteinsHot
Support

How to Order Shipping & Payments Global Distributors Testimonials Download Brochures Download COA
Application

The Process of How SARS-CoV-2 Infects the Host Quantitative Analysis of mAb in Serum Evaluation of CAR Expression
X-LAB
Company

About Us Join Us Contact Us
Activities

News Exhibitions Promotion
COVID-19 R&D ^New

Your Position: Home > LIGHT

LIGHT

LIGHT Molecule Information

Name:Tumor necrosis factor superfamily member 14
Target Synonym:Tumor Necrosis Factor Superfamily Member 14,Herpesvirus Entry Mediator Ligand,TNFSF14,CD258 Antigen,Herpes Virus Entry Mediator Ligand,Tumor Necrosis Factor Ligand 1D,LTg,HVEML,LIGHT,CD258,HVEM-L,Tumor Necrosis Factor (Ligand) Superfamily, Member 14,Tumor

Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

LIGHT Protein Product ListCompare or Buy

Product> Filter Results

Cat. No.	Species	Product Description
LIT-H5269	Human	Human LIGHT / TNFSF14 Protein, Fc Tag (active trimer) (MALS verified)
LIT-H5242	Human	Human LIGHT / TNFSF14 Protein, His Tag (active trimer) (MALS verified)
LIT-H5256	Human	Human LIGHT / TNFSF14 Protein, Mouse IgG2a Fc Tag, low endotoxin

LIGHT Part of Bioactivity data

LIT-H5269-Cell-based assay

Human FcRn Heterodimer Protein Cell_Base

Human LIGHT, Fc Tag (active trimer) (MALS verified) (Cat. No. LIT-H5269) induced cytotoxicity in HT-29 cells. The ED50 for this effect is 1.29-2.38 ng/mL (Routinely tested).

Protocol

LIT-H5242-Cell-based assay

Human LIGHT, His Tag (active trimer) (MALS verified) (Cat. No. LIT-H5242) induced cytotoxicity in HT-29 cells. The ED50 for this effect is 1.11-3.87 ng/mL (Routinely tested).

Protocol

LIT-H5256-BLI

Loaded Human DcR3, Fc Tag (Cat. No. TNB-H5255) on AHC Biosensor, can bind Human LIGHT, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. LIT-H5256) with an affinity constant of 1.64 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

LIT-H5242-ELISA

Immobilized Human HVEM, Fc Tag (Cat. No. HVM-H5258) at 5 μg/mL (100 μL/well) can bind Human LIGHT, His Tag (active trimer) (MALS verified) (Cat. No. LIT-H5242) with a linear range of 16-63 ng/mL (QC tested).

Protocol

LIGHT Molecule Synonym Name

CD258 antigen,CD258,HVEM-L,LIGHT,LTg,TNFSF14,TR2,HVEML

LIGHT Molecule Background

Tumor necrosis factor ligand superfamily member 14(LIGHT) is a tumor necrosis factor (TNF) superfamily ligand that regulates T cell immune responses by signaling through the herpes virus entry mediator (HVEM) and the lymphotoxin beta receptor (LTbetaR). LIGHT has emerged as a potent initiator of T cell co-stimulation signals effecting CTL-mediated tumor rejection, allograft rejection and graft versus host disease. Constitutive expression of LIGHT leads to tissue destruction and autoimmune-like disease syndromes.

LIGHT References

LIGHT Clinical Drug Information

Name	Research Code	Research Phase	Company	Indications	Clinical Trials
Anti-CD258 monoclonal antibody	CERC-002; MDGN-002; SAR-252067; AEVI-002	Phase 2 Clinical	La Jolla Pharmaceutical Company, Kyowa Hakko Kirin	Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Colitis, Ulcerative; Crohn Disease; Acute Lung Injury	Details